Essilor® Stellest® Lenses Multicentre European Study (SLOMES)
The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety, acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in slowing myopia progression in European children and adolescents. Participants will receive Essilor® Stellest® at inclusion visit and will be asked for a full time wear (>12 hours daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic autorefraction from baseline to 24 months compared to expected change based on axial length and refraction centile positions at baseline.
- EligibilityCriteria: Inclusion Criteria:  - Myopia as determined by cycloplegic autorefraction as follows:  Each meridian SER of plano to - 8;00 D in each eye Astigmatism < 2.50 D Anisometropia ≤ 1.50 D - Monocular corrected VA of at least 0.2 LogMAR in both eyes - Age: 6 - 16 years old, inclusive at the time of inclusion - Ability to understand treatment and give valid assent - Ability to comply with the protocol to get reliable study measurements  Exclusion Criteria:  - Concomitant or previous therapies for myopia  - Eye diseases/conditions:  Strabismus by cover test at near or distance Any ocular disease that would influence refractive development e.g. retinal disease, cataract, ptosis Any systemic or neurodevelopmental conditions that may influence refractive development - Use of ocular or systemic medication which may affect myopia progression or visual acuity through known effects on retina, accommodation, or significant elevation of intraocular pressure - Participation in another study which may influence vision or interfere with study assessments - Myopia onset before 5 years of age - Contact lens wearers - HealthyVolunteers: No - Gender: All - MinimumAge: 6 Years - MaximumAge: 16 Years - StdAgeList: Child